CA2205112C - Method and composition for treating mammalian diseases caused by inflammatory response - Google Patents
Method and composition for treating mammalian diseases caused by inflammatory response Download PDFInfo
- Publication number
- CA2205112C CA2205112C CA002205112A CA2205112A CA2205112C CA 2205112 C CA2205112 C CA 2205112C CA 002205112 A CA002205112 A CA 002205112A CA 2205112 A CA2205112 A CA 2205112A CA 2205112 C CA2205112 C CA 2205112C
- Authority
- CA
- Canada
- Prior art keywords
- pyruvate
- respiratory disease
- inflammatory mediator
- pharmaceutical composition
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response is disclosed.
Mammalian cells participating in the inflammatory response are contacted with an inflammatory response mediator which reduces the undesired inflammatory response and is an antioxidant. The inflammatory response mediator may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. Compositions for reducing and treating undesired inflammatory response are also disclosed.
Mammalian cells participating in the inflammatory response are contacted with an inflammatory response mediator which reduces the undesired inflammatory response and is an antioxidant. The inflammatory response mediator may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. Compositions for reducing and treating undesired inflammatory response are also disclosed.
Description
METHOD AND COMPOSITION FOR
TREATING MAMMALIAN DISEASES CAUSED
BY INFLAMMATORY RESPONSE
BACKGROUND OF THE INVENTION
1. Field of the Invention This invention pertains to therapeutic methods of preventing and treating the damage and resulting disease state in mammals caused by mammalian cells involved in the inflammatory response resulting in undesired respiratory bursting, production of enzymes and cellular signaling agents in mammalian cells.
This invention also pertains to compositions used in the therapeutic methods.
Description of the Prior Art Reactive oxygen species are generated by cells in response to inter alia aerobic metabolism, catabolism of drugs, toxins and other xenobiotics, ultraviolet and x-ray radiation and the respiratory burst of phagocytic cells (such as white blood cells) to kill invading bacteria and in response to foreign bodies. Hydrogen peroxide, for example, is produced during respiration of most living organisms especially by stressed and living cells.
These active oxygen species can injure cells. An important example of such damage is lipid peroxidation which involves the oxidative degradation of unsaturated lipids. Lipid peroxidation is highly detrimental to membrane structure and function and can cause numerous cytopathological effects. Cells defend against lipid peroxidation by producing radical scavengers such as superoxide dismutase, catalase, and peroxidase. Injured cells have a decreased ability to produce radical scavengers. Excess hydrogen peroxide can react with pyrimidines to open the 5, double-bond. This reaction inhibits the ability of pyrimidines to hydrogen bond to complementary bases (Hallaender et al. (1971), Chemical Mutagens , Principles and Methods for their Detection, edited by Alexander Hallaender, Division of Biology, Oak Ridge National Laboratory, Oak Ridge, Tennessee, Plenum Press. New York, pages 46-49). Such oxidative biochemical injury can result in the loss of cellular membrane integrity, reduced enzyme activity, changes in transport kinetics, changes in membrane lipid content, and leakage of potassium ions, amino acids, and other cellular material.
H; The production of reactive oxygen intermediates has been suggested to cause many skin, tissue, and organ disorders such as atherosclerosis, arthritis, cytotoxicity, skin inflammation, photoaging, wrinkling, actinic keratosis, tumor formation, cancer, hypertension, Parkinson's disease, lung disease, and heart disease. The role of active oxygen radicals in promoting tumors has been proposed based on the findings that (a) tumor promoters increase the level of oxygen radicals, (b) many free 'radical generating systems promote tumors, and (c) certain antioxidants inhibit the biochemical effects of tumor promoters.
In Vitro, reactive oxygen intermediates can be generated in cellular culture media by autooxidation and photooxidation of media components. During excision and storage, transplant organs can suffer oxidative injuries which result in thee loss of cellular membrane integrity and shorten the usable life of the organ.
When cells are stressed by oxidative injury, a resuscitation step is necessary to recondition the cells. Antioxidants have been shown to inhibit damage associated with active oxygen species. For example, pyruvate and other alphaketoacids have been reported to react rapidly and stoichiometrically with hydrogen peroxide to protect cells from cytolytic effects, O'Donnell-Tormey et ai., J. Exp. Med.. 165, pp. 500-514 (1987).
United States Patent No. 5,210,098 issued to Nath discloses a method to arrest or prevent acute kidney failure by administration of a non-toxic pyruvate salt to a patient in need of such treatment.
The Nath invention provides a therapeutic method comprising administration of an amount of pyruvate salt to a patient experiencing, or in danger of, acute renal failure. The pyruvate salt, preferably sodium pyruvate, is preferably dispersed or dissolved in a pharmaceutically acceptable liquid carrier and administered parenterally in an amount effective to arrest or prevent said acute renal failure, thus permitting restoration of normal kidney function. In some cases, the pyruvate may be infused directed into the kidney or into the proximal renal arterial circulation. The method is effective to prevent or counteract acute kidney failure due to a wide variety of causes, including, but not limited to, traumatic injury, including bum injury and obstruction; reperfusion following ischemia, inflammatory glomerulonephritis, and sepis, e.g. due to gram negative bacterial infection.
Martin et al., 1994, United States patent no. 5,296,370, discloses therapeutic compositions for preventing and reducing injury to mammalian cells and increasing the resuscitation rate of injured mammalian cells. In one embodiment, the therapeutic composition comprises (a) pyruvate selected from the group consisting of pyruvic acid, pharmaceutically acceptable salts of pyruvic acid, and mixtures thereof, (b) an antioxidant, and (c) a mixture of saturated and unsaturated fatty acids wherein the fatty acids are those fatty acids required for the resuscitation of injured mammalian cells.
United States Patent No. 5,256,697 issued to Miller et al., discloses a method for orally administering a therapeutically effective amount of pyruvate = 25 precursor to a mammal to improve insulin resistance, lower lasting insulin levels and reduce fat gain.
United States patent nos. 3,920,835, 3,984,556, and 3,988,470, all issued to Van Scott et al. disclose methods for treating acne, dandruff, and palmar keratosis, respectively, which consist of applying to the affected area a topical composition comprising from about 1% to about 20% of a lower aliphatic compound containing from two to six carbon atoms selected from the group consisting of alpha-hydroxyacids, alpha-ketoacids and esters thereof, and 3-hydroxybutryic acid in a pharmaceutically acceptable carrier. The aliphatic compounds include pyruvic acid and lactic acid.
United States patents nos. 4,105,783 and 4,197,316, both issued to Yu et al., disclose a method and composition, respectively, for treating dry skin which consists of applying to the affected area a topical composition comprising from about 1% to about 20% of a compound selected from the group consisting of amides and ammonium salts of alpha-hydroxyacids, beta-hydroxyacids, and alpha-ketoacids in a pharmaceutically acceptable carrier. The compounds include the amides and ammonium salts of pyruvic acid and lactic acid.
United States patent no. 4,234,599, issued to Van Scott et al., discloses a method for treating actinic and nonactinic skin keratoses which consists of applying to the affected area a topical composition comprising an effective amount of a compound selected from the group consisting of alpha-hydroxyacids, beta-hydroxyacids, and alpha-ketoacids in a pharmaceutically acceptable carrier.
The acidic compounds include pyruvic acid and lactic acid.
United States patent no. 4,294,852, issued to Wildnauer et al., discloses a composition for treating skin which comprises the alpha-hydroxyacids, beta-hydroxyacids, and alpha-ketoacids disclosed above by Van Scott et al. in =
combination with C3-C8 aliphatic alcohols.
United States patent no. 4,663,166, issued to Veech, discloses an electrolyte solution which comprises a mixture of L-lactate and pyruvate in a ratio from 20:1 to 1:1, respectively, or a mixture of D-beta-hydroxybutyrate and acetoacetate, in a ratio from 6:1 to 0.5:1, respectively.
~
Sodium pyruvate has been reported to reduce the number of erosions, 5 ulcers, and hemorrhages on the gastric mucosa in guinea pigs and rats caused by acetylsalicylic acid. The analgesic and antipyretic properties of acetylsalicylic acid were not impaired by sodium pyruvate, Puschmann, Arzneimittelforschun~, 33, pp.
410-415 and 415-416 (1983).
Pyruvate has been reported to exert a positive inotropic effect in stunned myocardium, which is a prolonged ventricular dysfunction following brief periods of coronary artery occlusions which does not produce irreversible damage, Mentzer et al., Ann.Surg., 209, pp. 629-633 (1989).
Pyruvate has been reported to produce a relative stabilization of left ventricular pressure and work parameter and to reduce the size of infarctions.
Pyruvate improves resumption of spontaneous beating of the heart and restoration of normal rates and pressure development, Bunger et al., J. Mol. Cell.
Cardiol., 18, pp. 423-438 (1986), Mochizuki et al., J. Physiol. Paris , 76S pp. 805-812 (1980), Regitz et al., Cardiovasc, Res., 15 pp. 652-658 (1981), Giannelli et al., Ann.Thorac.
Surg., 21 pp. 386-396. (1976).
Sodium pyruvate has been reported to act as an antagonist to cyanide intoxication (presumably through the formation of cyanohydrin) and to protect = 25 against the lethal effects of sodium sulfide and to retard the onset and development of functional, morphological, and biochemical measures of acrylamide neuropathy of axons, Schwartz et al., Toxicol. Appl. Pharmacol., 50 pp. 437-442 (1979), Sabri et al., Brain Res., 483, pp. 1-11 (1989).
TREATING MAMMALIAN DISEASES CAUSED
BY INFLAMMATORY RESPONSE
BACKGROUND OF THE INVENTION
1. Field of the Invention This invention pertains to therapeutic methods of preventing and treating the damage and resulting disease state in mammals caused by mammalian cells involved in the inflammatory response resulting in undesired respiratory bursting, production of enzymes and cellular signaling agents in mammalian cells.
This invention also pertains to compositions used in the therapeutic methods.
Description of the Prior Art Reactive oxygen species are generated by cells in response to inter alia aerobic metabolism, catabolism of drugs, toxins and other xenobiotics, ultraviolet and x-ray radiation and the respiratory burst of phagocytic cells (such as white blood cells) to kill invading bacteria and in response to foreign bodies. Hydrogen peroxide, for example, is produced during respiration of most living organisms especially by stressed and living cells.
These active oxygen species can injure cells. An important example of such damage is lipid peroxidation which involves the oxidative degradation of unsaturated lipids. Lipid peroxidation is highly detrimental to membrane structure and function and can cause numerous cytopathological effects. Cells defend against lipid peroxidation by producing radical scavengers such as superoxide dismutase, catalase, and peroxidase. Injured cells have a decreased ability to produce radical scavengers. Excess hydrogen peroxide can react with pyrimidines to open the 5, double-bond. This reaction inhibits the ability of pyrimidines to hydrogen bond to complementary bases (Hallaender et al. (1971), Chemical Mutagens , Principles and Methods for their Detection, edited by Alexander Hallaender, Division of Biology, Oak Ridge National Laboratory, Oak Ridge, Tennessee, Plenum Press. New York, pages 46-49). Such oxidative biochemical injury can result in the loss of cellular membrane integrity, reduced enzyme activity, changes in transport kinetics, changes in membrane lipid content, and leakage of potassium ions, amino acids, and other cellular material.
H; The production of reactive oxygen intermediates has been suggested to cause many skin, tissue, and organ disorders such as atherosclerosis, arthritis, cytotoxicity, skin inflammation, photoaging, wrinkling, actinic keratosis, tumor formation, cancer, hypertension, Parkinson's disease, lung disease, and heart disease. The role of active oxygen radicals in promoting tumors has been proposed based on the findings that (a) tumor promoters increase the level of oxygen radicals, (b) many free 'radical generating systems promote tumors, and (c) certain antioxidants inhibit the biochemical effects of tumor promoters.
In Vitro, reactive oxygen intermediates can be generated in cellular culture media by autooxidation and photooxidation of media components. During excision and storage, transplant organs can suffer oxidative injuries which result in thee loss of cellular membrane integrity and shorten the usable life of the organ.
When cells are stressed by oxidative injury, a resuscitation step is necessary to recondition the cells. Antioxidants have been shown to inhibit damage associated with active oxygen species. For example, pyruvate and other alphaketoacids have been reported to react rapidly and stoichiometrically with hydrogen peroxide to protect cells from cytolytic effects, O'Donnell-Tormey et ai., J. Exp. Med.. 165, pp. 500-514 (1987).
United States Patent No. 5,210,098 issued to Nath discloses a method to arrest or prevent acute kidney failure by administration of a non-toxic pyruvate salt to a patient in need of such treatment.
The Nath invention provides a therapeutic method comprising administration of an amount of pyruvate salt to a patient experiencing, or in danger of, acute renal failure. The pyruvate salt, preferably sodium pyruvate, is preferably dispersed or dissolved in a pharmaceutically acceptable liquid carrier and administered parenterally in an amount effective to arrest or prevent said acute renal failure, thus permitting restoration of normal kidney function. In some cases, the pyruvate may be infused directed into the kidney or into the proximal renal arterial circulation. The method is effective to prevent or counteract acute kidney failure due to a wide variety of causes, including, but not limited to, traumatic injury, including bum injury and obstruction; reperfusion following ischemia, inflammatory glomerulonephritis, and sepis, e.g. due to gram negative bacterial infection.
Martin et al., 1994, United States patent no. 5,296,370, discloses therapeutic compositions for preventing and reducing injury to mammalian cells and increasing the resuscitation rate of injured mammalian cells. In one embodiment, the therapeutic composition comprises (a) pyruvate selected from the group consisting of pyruvic acid, pharmaceutically acceptable salts of pyruvic acid, and mixtures thereof, (b) an antioxidant, and (c) a mixture of saturated and unsaturated fatty acids wherein the fatty acids are those fatty acids required for the resuscitation of injured mammalian cells.
United States Patent No. 5,256,697 issued to Miller et al., discloses a method for orally administering a therapeutically effective amount of pyruvate = 25 precursor to a mammal to improve insulin resistance, lower lasting insulin levels and reduce fat gain.
United States patent nos. 3,920,835, 3,984,556, and 3,988,470, all issued to Van Scott et al. disclose methods for treating acne, dandruff, and palmar keratosis, respectively, which consist of applying to the affected area a topical composition comprising from about 1% to about 20% of a lower aliphatic compound containing from two to six carbon atoms selected from the group consisting of alpha-hydroxyacids, alpha-ketoacids and esters thereof, and 3-hydroxybutryic acid in a pharmaceutically acceptable carrier. The aliphatic compounds include pyruvic acid and lactic acid.
United States patents nos. 4,105,783 and 4,197,316, both issued to Yu et al., disclose a method and composition, respectively, for treating dry skin which consists of applying to the affected area a topical composition comprising from about 1% to about 20% of a compound selected from the group consisting of amides and ammonium salts of alpha-hydroxyacids, beta-hydroxyacids, and alpha-ketoacids in a pharmaceutically acceptable carrier. The compounds include the amides and ammonium salts of pyruvic acid and lactic acid.
United States patent no. 4,234,599, issued to Van Scott et al., discloses a method for treating actinic and nonactinic skin keratoses which consists of applying to the affected area a topical composition comprising an effective amount of a compound selected from the group consisting of alpha-hydroxyacids, beta-hydroxyacids, and alpha-ketoacids in a pharmaceutically acceptable carrier.
The acidic compounds include pyruvic acid and lactic acid.
United States patent no. 4,294,852, issued to Wildnauer et al., discloses a composition for treating skin which comprises the alpha-hydroxyacids, beta-hydroxyacids, and alpha-ketoacids disclosed above by Van Scott et al. in =
combination with C3-C8 aliphatic alcohols.
United States patent no. 4,663,166, issued to Veech, discloses an electrolyte solution which comprises a mixture of L-lactate and pyruvate in a ratio from 20:1 to 1:1, respectively, or a mixture of D-beta-hydroxybutyrate and acetoacetate, in a ratio from 6:1 to 0.5:1, respectively.
~
Sodium pyruvate has been reported to reduce the number of erosions, 5 ulcers, and hemorrhages on the gastric mucosa in guinea pigs and rats caused by acetylsalicylic acid. The analgesic and antipyretic properties of acetylsalicylic acid were not impaired by sodium pyruvate, Puschmann, Arzneimittelforschun~, 33, pp.
410-415 and 415-416 (1983).
Pyruvate has been reported to exert a positive inotropic effect in stunned myocardium, which is a prolonged ventricular dysfunction following brief periods of coronary artery occlusions which does not produce irreversible damage, Mentzer et al., Ann.Surg., 209, pp. 629-633 (1989).
Pyruvate has been reported to produce a relative stabilization of left ventricular pressure and work parameter and to reduce the size of infarctions.
Pyruvate improves resumption of spontaneous beating of the heart and restoration of normal rates and pressure development, Bunger et al., J. Mol. Cell.
Cardiol., 18, pp. 423-438 (1986), Mochizuki et al., J. Physiol. Paris , 76S pp. 805-812 (1980), Regitz et al., Cardiovasc, Res., 15 pp. 652-658 (1981), Giannelli et al., Ann.Thorac.
Surg., 21 pp. 386-396. (1976).
Sodium pyruvate has been reported to act as an antagonist to cyanide intoxication (presumably through the formation of cyanohydrin) and to protect = 25 against the lethal effects of sodium sulfide and to retard the onset and development of functional, morphological, and biochemical measures of acrylamide neuropathy of axons, Schwartz et al., Toxicol. Appl. Pharmacol., 50 pp. 437-442 (1979), Sabri et al., Brain Res., 483, pp. 1-11 (1989).
A chemotherapeutic cure of advanced L1210 leukemia has been reported using sodium pyruvate to restore abnormally deformed red blood cells to normal. The deformed red blood cells prevented adequate drug delivery to tumor cells, Cohen. Cancer Chemother, Pharmacol., 5, pp. 175-179 (1981).
Primary cultures of heterotopic tracheal transplant exposed in vivo to 7, 12-dimethylbenz(a)anthracene were reported to be successfully maintained in enrichment medium supplemented with sodium pyruvate along with cultures of interleukin-2 stimulated peripheral blood lymphocytes, and plasmacytomas and hybridomas, pig embryos, and human blastocysts, Shacter, J. Immunol, Methods, 99 pp. 259-270 (1987), Marchok et al.. Cancer Res., 37 pp. 1811-1821 (1977), Davis, J. Reprod. Fertil, Suppi., 33, pp 115-124 (1985), Okamoto et al., No To Shinkei, 38, pp. 593-598 (1986), Cohen et al., J. In Vitro Fert. Embryo Transfer, 2, pp. 59-64 (1985).
United States patents nos. 4,158,057, 4,351,835, 4,415,576, and 4,645,764, all issued to Stanko, disclose methods for preventing the accumulation of fat in the liver of a mammal due to the ingestion of alcohol, for controlling weight in a mammal, for inhibiting body fat while increasing protein concentration in a mammal, and for controlling the deposition of body fat in a living being, respectively. The methods comprise administering to the mammal a therapeutic mixture of pyruvate and dihydroxyacetone, and optionally riboflavin. United States patent no. 4,548,937, issued to Stanko, discloses a method for controlling the weight gain of a mammal which comprises administering to the mammal a therapeutically effective amount of pyruvate, and optionally riboflavin. United States patent no =
4,812,479, issued to Stanko, discloses a method for controlling the weight gain of a mammal which comprises administering to the mammal a therapeutically effective amount of dihydroxyacetone, and optionally riboflavin and pyruvate.
Primary cultures of heterotopic tracheal transplant exposed in vivo to 7, 12-dimethylbenz(a)anthracene were reported to be successfully maintained in enrichment medium supplemented with sodium pyruvate along with cultures of interleukin-2 stimulated peripheral blood lymphocytes, and plasmacytomas and hybridomas, pig embryos, and human blastocysts, Shacter, J. Immunol, Methods, 99 pp. 259-270 (1987), Marchok et al.. Cancer Res., 37 pp. 1811-1821 (1977), Davis, J. Reprod. Fertil, Suppi., 33, pp 115-124 (1985), Okamoto et al., No To Shinkei, 38, pp. 593-598 (1986), Cohen et al., J. In Vitro Fert. Embryo Transfer, 2, pp. 59-64 (1985).
United States patents nos. 4,158,057, 4,351,835, 4,415,576, and 4,645,764, all issued to Stanko, disclose methods for preventing the accumulation of fat in the liver of a mammal due to the ingestion of alcohol, for controlling weight in a mammal, for inhibiting body fat while increasing protein concentration in a mammal, and for controlling the deposition of body fat in a living being, respectively. The methods comprise administering to the mammal a therapeutic mixture of pyruvate and dihydroxyacetone, and optionally riboflavin. United States patent no. 4,548,937, issued to Stanko, discloses a method for controlling the weight gain of a mammal which comprises administering to the mammal a therapeutically effective amount of pyruvate, and optionally riboflavin. United States patent no =
4,812,479, issued to Stanko, discloses a method for controlling the weight gain of a mammal which comprises administering to the mammal a therapeutically effective amount of dihydroxyacetone, and optionally riboflavin and pyruvate.
Rats fed a calcium-oxalate lithogenic diet including sodium pyruvate were reported to develop fewer urinary calculi (stones) than control rats not given sodium pyruvate, Ogawa et al., Hinvokika Kivo, 32, pp. 1341-1347 (1986).
United States patent no. 4,521,375, issued to Houlsby, discloses a method for sterilizing surfaces which come into contact with living tissue.
The method comprises sterilizing the surface with aqueous hydrogen peroxide and then neutralizing the surface with pyruvic acid.
United States patent no. 4,416,982, issued to Tauda et al., discloses a method for decomposing hydrogen peroxide by reacting the hydrogen peroxide with a phenol or aniline derivative in the presence of peroxidase.
United States patent no, 4,696,917, issued to Lindstrom et al., discloses an irrigation solution which comprises Eagle's Minimum Essential Medium with Earle's salts, chondroitin sulfate, a buffer solution, 2-mercaptoethanol, and a pyruvate. The irrigation solution may optionally contain ascorbic acid and alpha-tocopherol. United States patent no. 4,725,586, issued to Lindstrom et al., discloses an irrigation solution which comprises a balanced salt solution, chondroitin sulfate, a buffer solution, 2 mercaptoethanol, sodium bicarbonate or dextrose, a pyruvate, a sodium phosphate buffer system, and cystine. The irrigation solution may optionally contain ascorbic acid and gamma-tocopherol.
United States patent no. 4,847,069, issued to Bissett et al., discloses a photoprotective composition comprising (a) a sorbohydroxamic acid, (b) an anti-inflammatory agent selected from steroidal anti-inflammatory agents and a natural anti-inflammatory agent, and (c) a topical carrier. Fatty acids may be present as an emollient. United States patent no. 4,847,071, issued to Bissett et al., discloses a photoprotective composition comprising (a) a tocopherol or tocopherol ester radical scavenger, (b) an anti-inflammatory agent selected from steroidal anti-inflammatory agents and a natural anti-inflammatory agent, and (c) a topical carrier.
United States patent no. 4,847,072, issued to Bissett et al., discloses a topical composition comprising not more than 25% tocopherol sorbate in a topical carrier.
The addition of sodium pyruvate to bacterial and yeast systems has been reported to inhibit hydrogen peroxide production, enhance growth, and protect the systems against the toxicity of reactive oxygen intermediates. The optimum ratio of unsaturated to saturated fatty acids contained within chicken fat enhanced membrane repair and reduced cytotoxicity. The antioxidants glutathione and thioglycollate reduced the injury induced by oxygen radical species (thesis of Alain Martin, "A resuscitation medium for the rapid detection and isolation of injured Salmonella, Escherichia coli, Staphylococcus aureus, and listeria in food". A dissertation submitted to the Graduate School in New Brunswick; Rutgers, The State University of New Jersey, The Graduate School of Biological Sciences, May 1989).
While the above therapeutic compositions and methods are reported to inhibit the production of reactive oxygen intermediates, none of the compositions and methods treats the damage and resulting disease state in mammals caused by undesired respiratory bursting, production of enzymes and cellular signaling agents in mammalian cells.
SUNIlMARY OF THE INVENTION
The present invention pertains to a method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response and compositions useful in the method. The method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response comprises: contacting the mammalian cells participating in the inflammatory response with an inflammatory mediator; wherein the inflammatory mediator is present in an amount capable of reducing the undesired inflammatory response and is an antioxidant.
In embodiments, the inflammatory mediator is selected from pyruvic acid, a salt of pyruvate and a pyruvate precursor.
The inflammatory mediator in addition to reducing the undesired inflammatory response and being an antioxidant, may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. The inflammatory mediator may also increase cellular metabolic rate.
The present invention also pertains to compositions for reducing and treating the disease state in mammals caused by undesired inflammatory response comprising: an inflammatory response mediator; and a carrier composition; wherein the inflammatory response mediator is an antioxidant and capable of reducing undesired inflammatory response in mammalian cells.
The inflammatory response mediators may be used individually, in combination and further in combination with a therapeutic agent such as an antibacterial, antiviral, antifungal, protein, enzyme, antihistamine, hormone, nonsteroidal anti-inflammatory, cytokine, and steroid.
A preferred method of administering the inflammatory mediator is by inhalation.
9a Thus, in one aspect, the present invention provides use of an inflammatory mediator selected from pyruvic acid, a salt of pyruvate, and a pyruvate precursor, in the preparation of a medicament for the treatment of inflammation associated with a respiratory disease in a mammal.
In another aspect, the present invention provides use for treatinginflammation associated with a respiratory disease in a mammal of an inflammatory mediator selected from pyruvic acid, a salt of pyruvate, and a pyruvate precursor.
According to another aspect of the present invention, there is provided a pharmaceutical composition for treating inflammation associated with a respiratory disease in a mammal, comprising a therapeutically effective amount of an inflammatory mediator selected from pyruvic acid, a salt of pyruvate, and a pyruvate precursor, together with a pharmaceutically acceptable carrier.
According to still another aspect of the present invention, there is provided a commercial package comprising the pharmaceutical composition as described herein, together with instructions for treatment of inflammation associated with a respiratory disease in a mammal.
DETAILED DESCRIPTION OF THE INVENTION
Therapeutic compositions and a method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response have been discovered. The mammalian cells primarily responsible for the inflammatory 5 response are white blood cells or leucocytes.
In a method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response, mammalian cells are contacted with an inflammatory mediator. The inflammatory mediator is present in an amount capable of reducing the undesired inflammatory response and is an 10 antioxidant.
The inflammatory response, often referred to as respiratory bursting, is the response of defensive mammalian cells primarily white blood cells or leucocytes. These cells normally respond to an injury or invasion of the mammal by releasing a number of active compounds at the injury or invasion site.
Among the compounds released are enzymes such as proteases and active oxygen species such as hydrogen peroxide.
A purpose of the respiratory burst is to provide a battery of oxidizing agents in response to a stimulant that can be used by the leucocytes for the destruction of foreign cells, viruses, particulates and some toxins which have been ingested by or are in the vicinity of the leucocyte. The term "respiratory burst"
refers to a coordinated series of metabolic events that take place when leucocytes are exposed to appropriate stimuli. This group of events underlies all oxygen dependent killings by leucocytes.
The first of these events is the sharp increase in oxygen uptake that occurs upon stimulation of the leucocytes. While oxygen consumption by resting leucocytes varies widely by cell type, all respond to appropriate stimuli with an increase in oxygen uptake.
Stimulation of the leucocyte also causes an increase in glucose oxidation via the hexose monophosphate shunt. The hexose monophosphate shunt is a metabolic pathway in which glucose is oxidized to carbon dioxide and a five carbon sugar, with NADP+ serving as electron acceptor. Activation of the hexose monophosphate shunt therefore means that the oxidation of NADPH to NADP+
increases during the respiratory burst.
The respiratory burst produces superoxide and hydrogen peroxide.
Oxygen taken up by the respiratory burst is converted to superoxide. Hydrogen peroxide appears to arise during the respiratory burst mainly from the dismutation of superoxide anion.
0-2 + 0-2 + 2H+ H2 02 + 02 It has been demonstrated by Root and Metcalf and reported in J. Clin.
Invest. 60:1266 that 80 percent of the superoxide is converted to hydrogen peroxide, and this dismutation reaction is the only important source of the hydrogen peroxide generated during the burst. Hydrogen peroxide and superoxide are believed to be responsible for the killing by leucocytes.
Many agents, both soluble and particulate, are able to activate the respiratory burst. Particulate activating agents include bacteria, viruses and fungi for internal body organs or areas and bacteria, viruses, fungi, fibers, smoke, dust, ash, pollen, smog and the like for body cavities and organs such as the lungs, skin, digestive and excretory tracks open to the environment. Soluble agents can be toxins, medicinal compounds and soluble excretions of bacteria, fungi and infected mammalian cells and the like.
Activation of the respiratory burst in leucocytes usually follows exposure to the stimulus for less than a minute. Upon stimulation of the respiratory burst, the consumption of oxygen in leucocytes increases by over 100 fold resulting . 25 in, among other things, the production of superoxide, peroxide and hydrogen peroxide. The term "leucocytes" as used herein includes lymphocytes, phagocytes, macrophages and auxiliary cells.
Usually, after respiratory bursting the stimulant and/or the mechanism of stimulation turns off allowing the leucocyte to return to its normal resting state.
United States patent no. 4,521,375, issued to Houlsby, discloses a method for sterilizing surfaces which come into contact with living tissue.
The method comprises sterilizing the surface with aqueous hydrogen peroxide and then neutralizing the surface with pyruvic acid.
United States patent no. 4,416,982, issued to Tauda et al., discloses a method for decomposing hydrogen peroxide by reacting the hydrogen peroxide with a phenol or aniline derivative in the presence of peroxidase.
United States patent no, 4,696,917, issued to Lindstrom et al., discloses an irrigation solution which comprises Eagle's Minimum Essential Medium with Earle's salts, chondroitin sulfate, a buffer solution, 2-mercaptoethanol, and a pyruvate. The irrigation solution may optionally contain ascorbic acid and alpha-tocopherol. United States patent no. 4,725,586, issued to Lindstrom et al., discloses an irrigation solution which comprises a balanced salt solution, chondroitin sulfate, a buffer solution, 2 mercaptoethanol, sodium bicarbonate or dextrose, a pyruvate, a sodium phosphate buffer system, and cystine. The irrigation solution may optionally contain ascorbic acid and gamma-tocopherol.
United States patent no. 4,847,069, issued to Bissett et al., discloses a photoprotective composition comprising (a) a sorbohydroxamic acid, (b) an anti-inflammatory agent selected from steroidal anti-inflammatory agents and a natural anti-inflammatory agent, and (c) a topical carrier. Fatty acids may be present as an emollient. United States patent no. 4,847,071, issued to Bissett et al., discloses a photoprotective composition comprising (a) a tocopherol or tocopherol ester radical scavenger, (b) an anti-inflammatory agent selected from steroidal anti-inflammatory agents and a natural anti-inflammatory agent, and (c) a topical carrier.
United States patent no. 4,847,072, issued to Bissett et al., discloses a topical composition comprising not more than 25% tocopherol sorbate in a topical carrier.
The addition of sodium pyruvate to bacterial and yeast systems has been reported to inhibit hydrogen peroxide production, enhance growth, and protect the systems against the toxicity of reactive oxygen intermediates. The optimum ratio of unsaturated to saturated fatty acids contained within chicken fat enhanced membrane repair and reduced cytotoxicity. The antioxidants glutathione and thioglycollate reduced the injury induced by oxygen radical species (thesis of Alain Martin, "A resuscitation medium for the rapid detection and isolation of injured Salmonella, Escherichia coli, Staphylococcus aureus, and listeria in food". A dissertation submitted to the Graduate School in New Brunswick; Rutgers, The State University of New Jersey, The Graduate School of Biological Sciences, May 1989).
While the above therapeutic compositions and methods are reported to inhibit the production of reactive oxygen intermediates, none of the compositions and methods treats the damage and resulting disease state in mammals caused by undesired respiratory bursting, production of enzymes and cellular signaling agents in mammalian cells.
SUNIlMARY OF THE INVENTION
The present invention pertains to a method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response and compositions useful in the method. The method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response comprises: contacting the mammalian cells participating in the inflammatory response with an inflammatory mediator; wherein the inflammatory mediator is present in an amount capable of reducing the undesired inflammatory response and is an antioxidant.
In embodiments, the inflammatory mediator is selected from pyruvic acid, a salt of pyruvate and a pyruvate precursor.
The inflammatory mediator in addition to reducing the undesired inflammatory response and being an antioxidant, may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. The inflammatory mediator may also increase cellular metabolic rate.
The present invention also pertains to compositions for reducing and treating the disease state in mammals caused by undesired inflammatory response comprising: an inflammatory response mediator; and a carrier composition; wherein the inflammatory response mediator is an antioxidant and capable of reducing undesired inflammatory response in mammalian cells.
The inflammatory response mediators may be used individually, in combination and further in combination with a therapeutic agent such as an antibacterial, antiviral, antifungal, protein, enzyme, antihistamine, hormone, nonsteroidal anti-inflammatory, cytokine, and steroid.
A preferred method of administering the inflammatory mediator is by inhalation.
9a Thus, in one aspect, the present invention provides use of an inflammatory mediator selected from pyruvic acid, a salt of pyruvate, and a pyruvate precursor, in the preparation of a medicament for the treatment of inflammation associated with a respiratory disease in a mammal.
In another aspect, the present invention provides use for treatinginflammation associated with a respiratory disease in a mammal of an inflammatory mediator selected from pyruvic acid, a salt of pyruvate, and a pyruvate precursor.
According to another aspect of the present invention, there is provided a pharmaceutical composition for treating inflammation associated with a respiratory disease in a mammal, comprising a therapeutically effective amount of an inflammatory mediator selected from pyruvic acid, a salt of pyruvate, and a pyruvate precursor, together with a pharmaceutically acceptable carrier.
According to still another aspect of the present invention, there is provided a commercial package comprising the pharmaceutical composition as described herein, together with instructions for treatment of inflammation associated with a respiratory disease in a mammal.
DETAILED DESCRIPTION OF THE INVENTION
Therapeutic compositions and a method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response have been discovered. The mammalian cells primarily responsible for the inflammatory 5 response are white blood cells or leucocytes.
In a method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response, mammalian cells are contacted with an inflammatory mediator. The inflammatory mediator is present in an amount capable of reducing the undesired inflammatory response and is an 10 antioxidant.
The inflammatory response, often referred to as respiratory bursting, is the response of defensive mammalian cells primarily white blood cells or leucocytes. These cells normally respond to an injury or invasion of the mammal by releasing a number of active compounds at the injury or invasion site.
Among the compounds released are enzymes such as proteases and active oxygen species such as hydrogen peroxide.
A purpose of the respiratory burst is to provide a battery of oxidizing agents in response to a stimulant that can be used by the leucocytes for the destruction of foreign cells, viruses, particulates and some toxins which have been ingested by or are in the vicinity of the leucocyte. The term "respiratory burst"
refers to a coordinated series of metabolic events that take place when leucocytes are exposed to appropriate stimuli. This group of events underlies all oxygen dependent killings by leucocytes.
The first of these events is the sharp increase in oxygen uptake that occurs upon stimulation of the leucocytes. While oxygen consumption by resting leucocytes varies widely by cell type, all respond to appropriate stimuli with an increase in oxygen uptake.
Stimulation of the leucocyte also causes an increase in glucose oxidation via the hexose monophosphate shunt. The hexose monophosphate shunt is a metabolic pathway in which glucose is oxidized to carbon dioxide and a five carbon sugar, with NADP+ serving as electron acceptor. Activation of the hexose monophosphate shunt therefore means that the oxidation of NADPH to NADP+
increases during the respiratory burst.
The respiratory burst produces superoxide and hydrogen peroxide.
Oxygen taken up by the respiratory burst is converted to superoxide. Hydrogen peroxide appears to arise during the respiratory burst mainly from the dismutation of superoxide anion.
0-2 + 0-2 + 2H+ H2 02 + 02 It has been demonstrated by Root and Metcalf and reported in J. Clin.
Invest. 60:1266 that 80 percent of the superoxide is converted to hydrogen peroxide, and this dismutation reaction is the only important source of the hydrogen peroxide generated during the burst. Hydrogen peroxide and superoxide are believed to be responsible for the killing by leucocytes.
Many agents, both soluble and particulate, are able to activate the respiratory burst. Particulate activating agents include bacteria, viruses and fungi for internal body organs or areas and bacteria, viruses, fungi, fibers, smoke, dust, ash, pollen, smog and the like for body cavities and organs such as the lungs, skin, digestive and excretory tracks open to the environment. Soluble agents can be toxins, medicinal compounds and soluble excretions of bacteria, fungi and infected mammalian cells and the like.
Activation of the respiratory burst in leucocytes usually follows exposure to the stimulus for less than a minute. Upon stimulation of the respiratory burst, the consumption of oxygen in leucocytes increases by over 100 fold resulting . 25 in, among other things, the production of superoxide, peroxide and hydrogen peroxide. The term "leucocytes" as used herein includes lymphocytes, phagocytes, macrophages and auxiliary cells.
Usually, after respiratory bursting the stimulant and/or the mechanism of stimulation turns off allowing the leucocyte to return to its normal resting state.
When the bursting does not turn off, the inflammatory action of the leucocytes continues unchecked causing a number of disease states. These disease states occur as the compounds produced by the leucocytes attack, injure and kill tissue cells and other leucocytes. It is this failure to turn off the respiratory burst and the resulting injury to surrounding tissue cells, blood cells, other leucocytes and injured cells that produces the disease states treated by the present invention. Undesired inflammatory response occurs when the inflammatory response causes injury to host cells and this injury poses an independent threat to the host.
In a preferred embodiment, the therapeutic compositions containing an inflammatory mediator are administered locally to the site of inflammation.
In another preferred embodiment, the therapeutic compositions are administered systemically. In yet another preferred embodiment, the therapeutic compositions are administered systemically and locally concomitantly.
In a preferred embodiment, the therapeutic compositions are administered by inhalation. The therapeutic compositions may be first nebulized by any suitable means. The therapeutic compositions may be in liquid or solid form with liquid droplets or particle size being small enough to facilitate access to lung tissue by inhalation.
In another preferred embodiment, a sterile solution of therapeutic agent is nebulized and inhaled by the patient. A therapeutically effective amount of inflammatory medication is inhaled. This may be accomplished in a single inhalation or by repeated inhalations over a period of time typically 1 to 30 minutes.
Preferably, inhalation will be complete in less than 20 minutes. Most preferably inhalation will be complete in less than 15 minutes.
The term "injured cell" as used herein means a cell which has some =
or all of the following: (a) injured membranes so that transport through the membranes is diminished and may result in one or more of the following, an increase in toxins and normal cellular wastes inside the cell and/or a decrease in nutrients and other components necessary for cellular repair inside the cell, (b) an increase in concentration of oxygen radicals inside the cell because of the decreased ability of the cell to produce antioxidants and enzymes, and (c) damaged DNA, RNA and ribosomes which must be repaired or replaced before normal cellular functions can be resumed.
Preferably the inflammatory mediator when brought into contact with a mammalian cell provides a cellular energy source and a building block in the cellular synthesis of other cellular components.
The inflammatory response being reduced is at least one of the following: oxygen radical production, peroxide production, cytokine and/or protease production, prostiglandin production, erythema, histamine and interlukin production and like responses known in the art as inflammatory responses.
The preferred inflammatory mediator is at least one compound selected from the group consisting of a pyruvate precursor, pyruvic acid, a salt of pyruvate, a lactate precursor and lactate. A precursor is a substance from which another substance is formed and in this text also includes salts.
Preferably the pyruvate salt is selected from the group consisting of lithium pyruvate, sodium pyruvate, potassium pyruvate, magnesium pyruvate, calcium pyruvate, zinc pyruvate, manganese pyruvate, and the like and mixtures thereof. Sodium pyruvate is most preferred.
Another preferred inflammatory mediator is selected from the group consisting of pyruvyl-glycene, pyruvyl-alanine, pyruvyl-leucine, pyruvyl-valine, pyruvyl-isoleucine, pyruvyl-phenylalanine, pyruvamide, dihydroxyacetone, and propylene glycol.
Preferred salts of the inflammation mediator are salts that do not produce an adverse effect on the mammalian cell when applied as a salt of the inflammation mediator. Typical salts would be the lithium, sodium, potassium, aluminum, magnesium, calcium, zinc, manganese, ammonium and the like and mixtures thereof.
The lactate precursor is preferably selected from the group consisting of lactyl-glycene, lactyl-alanine, lactyl-leucine, lactyl-valine, lactyl-isoleucine, lactyI-phenylalanine, lactamide and the various salts of lactate.
Compositions for reducing and treating the disease state in mammals caused by undesired inflammatory response comprise:
an inflammatory response mediator; and a carrier composition.
The carrier composition is selected from the group consisting of tablets, capsules, liquids, isotonic liquids, isotonic media, enteric tablets and capsules, parenterals, topicals, creams, gels, ointments, chewing gums, confections and the like.
The inflammatory mediator is administered in a therapeutically effective amount to reduce the undesired inflammatory response. Preferably from 0.00 1 to 10 grams per dose. More preferably 0.001 to 1 gram per dose and most preferably 0.001 to 0_25 grams per dose. It is understood that the method of administration and the condition being treated will greatly affect the dose required to achieve the therapeutic effect.
Typical respiratory diseases treatable by the present composition and method include but are not limited to bronchial asthma, acute bronchitis, emphysema, chronic obstructive emphysema, centrilobular emphysema, panacinar emphysema, chronic obstructive bronchitis, reactive airway disease, cystic fibrosis, bronchiectasis, acquired bronchiectasis, kartaagener's syndrome, atelectasis, acute atelectasis, chronic atelectasis, pneumonia, essential thrombocytopenia, legionnaires disease, psittacosis, fibrogenic dust disease, diseases due to organic dust, diseases due to irritant gases and chemicals, hypersensitivity diseases of the lung, idiopathic infiltrative diseases of the lungs and the like.
Particular disease states to be treated are emphysema and asthma.
The inflammatory mediator of the present invention may be administered prior to, after and/or with other therapeutic agents. Typical therapeutic agents are antibacterials, antivirals, antifungals, antihistamines, proteins, enzymes, hormones, nonsteroidal anti-inflammatories, cytokines, steroids, and the like.
Obviously, numerous modifications and variations of the present invention are possible in the light of the above teachings and the invention is not limited to the example herein. It is therefore understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically 5 described herein.
Example Subject: A 59 year old male suffering from emphysema and restrictive airway disease was treated as described below for three (3) months. Prior to treatment the 10 subject had limited capacity to breathe, did not respond to any other treatment, was on oxygen daily, and could not function at work (was on sabbatical leave).
After three (3) months treatment he showed marked improvement. In fact, dramatic results were observed within two (2) weeks.
Treatment: The treatment was conducted as follows:
In a preferred embodiment, the therapeutic compositions containing an inflammatory mediator are administered locally to the site of inflammation.
In another preferred embodiment, the therapeutic compositions are administered systemically. In yet another preferred embodiment, the therapeutic compositions are administered systemically and locally concomitantly.
In a preferred embodiment, the therapeutic compositions are administered by inhalation. The therapeutic compositions may be first nebulized by any suitable means. The therapeutic compositions may be in liquid or solid form with liquid droplets or particle size being small enough to facilitate access to lung tissue by inhalation.
In another preferred embodiment, a sterile solution of therapeutic agent is nebulized and inhaled by the patient. A therapeutically effective amount of inflammatory medication is inhaled. This may be accomplished in a single inhalation or by repeated inhalations over a period of time typically 1 to 30 minutes.
Preferably, inhalation will be complete in less than 20 minutes. Most preferably inhalation will be complete in less than 15 minutes.
The term "injured cell" as used herein means a cell which has some =
or all of the following: (a) injured membranes so that transport through the membranes is diminished and may result in one or more of the following, an increase in toxins and normal cellular wastes inside the cell and/or a decrease in nutrients and other components necessary for cellular repair inside the cell, (b) an increase in concentration of oxygen radicals inside the cell because of the decreased ability of the cell to produce antioxidants and enzymes, and (c) damaged DNA, RNA and ribosomes which must be repaired or replaced before normal cellular functions can be resumed.
Preferably the inflammatory mediator when brought into contact with a mammalian cell provides a cellular energy source and a building block in the cellular synthesis of other cellular components.
The inflammatory response being reduced is at least one of the following: oxygen radical production, peroxide production, cytokine and/or protease production, prostiglandin production, erythema, histamine and interlukin production and like responses known in the art as inflammatory responses.
The preferred inflammatory mediator is at least one compound selected from the group consisting of a pyruvate precursor, pyruvic acid, a salt of pyruvate, a lactate precursor and lactate. A precursor is a substance from which another substance is formed and in this text also includes salts.
Preferably the pyruvate salt is selected from the group consisting of lithium pyruvate, sodium pyruvate, potassium pyruvate, magnesium pyruvate, calcium pyruvate, zinc pyruvate, manganese pyruvate, and the like and mixtures thereof. Sodium pyruvate is most preferred.
Another preferred inflammatory mediator is selected from the group consisting of pyruvyl-glycene, pyruvyl-alanine, pyruvyl-leucine, pyruvyl-valine, pyruvyl-isoleucine, pyruvyl-phenylalanine, pyruvamide, dihydroxyacetone, and propylene glycol.
Preferred salts of the inflammation mediator are salts that do not produce an adverse effect on the mammalian cell when applied as a salt of the inflammation mediator. Typical salts would be the lithium, sodium, potassium, aluminum, magnesium, calcium, zinc, manganese, ammonium and the like and mixtures thereof.
The lactate precursor is preferably selected from the group consisting of lactyl-glycene, lactyl-alanine, lactyl-leucine, lactyl-valine, lactyl-isoleucine, lactyI-phenylalanine, lactamide and the various salts of lactate.
Compositions for reducing and treating the disease state in mammals caused by undesired inflammatory response comprise:
an inflammatory response mediator; and a carrier composition.
The carrier composition is selected from the group consisting of tablets, capsules, liquids, isotonic liquids, isotonic media, enteric tablets and capsules, parenterals, topicals, creams, gels, ointments, chewing gums, confections and the like.
The inflammatory mediator is administered in a therapeutically effective amount to reduce the undesired inflammatory response. Preferably from 0.00 1 to 10 grams per dose. More preferably 0.001 to 1 gram per dose and most preferably 0.001 to 0_25 grams per dose. It is understood that the method of administration and the condition being treated will greatly affect the dose required to achieve the therapeutic effect.
Typical respiratory diseases treatable by the present composition and method include but are not limited to bronchial asthma, acute bronchitis, emphysema, chronic obstructive emphysema, centrilobular emphysema, panacinar emphysema, chronic obstructive bronchitis, reactive airway disease, cystic fibrosis, bronchiectasis, acquired bronchiectasis, kartaagener's syndrome, atelectasis, acute atelectasis, chronic atelectasis, pneumonia, essential thrombocytopenia, legionnaires disease, psittacosis, fibrogenic dust disease, diseases due to organic dust, diseases due to irritant gases and chemicals, hypersensitivity diseases of the lung, idiopathic infiltrative diseases of the lungs and the like.
Particular disease states to be treated are emphysema and asthma.
The inflammatory mediator of the present invention may be administered prior to, after and/or with other therapeutic agents. Typical therapeutic agents are antibacterials, antivirals, antifungals, antihistamines, proteins, enzymes, hormones, nonsteroidal anti-inflammatories, cytokines, steroids, and the like.
Obviously, numerous modifications and variations of the present invention are possible in the light of the above teachings and the invention is not limited to the example herein. It is therefore understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically 5 described herein.
Example Subject: A 59 year old male suffering from emphysema and restrictive airway disease was treated as described below for three (3) months. Prior to treatment the 10 subject had limited capacity to breathe, did not respond to any other treatment, was on oxygen daily, and could not function at work (was on sabbatical leave).
After three (3) months treatment he showed marked improvement. In fact, dramatic results were observed within two (2) weeks.
Treatment: The treatment was conducted as follows:
15 Five (5) milliliters of five (5) millimolar sodium pyruvate solution is filter sterilized through a 0.2 micron filter. The sterile pyruvate solution is placed into a Pulmo Aid*" nebulizer manufactured by DeVilbiss Co., Somerset, Pennsylvania 15501-0635. The sterile pyruvate solution is nebulized by the Pulmo Aid device fitted with a disposable nebulizer and inhaled by the patient. The patient inhales normally from the Pulmo Aid nebulizer until all of the solution has been nebulized and inhaled. This inhalation step typicaliy takes about ten (10) to twenty (20) minutes.
The patient is treated with this inhalation therapy periodically.
Initially, treatments are about four (4) times a day at about six (6) hour intervals.
Treatments were reduced to three (3) times a day at about eight (8) hour intervals after 30 days of therapy. Treatments were further reduced to once a day 60 DAYS
AFTER ONSET OF TREATMENT. After ninety (90) days treatments are three to five times a week.
The following data shows results of various lung capacity and lung *Trade-mark function tests administered before treatment and two (2) months after treatment was commenced.
Before After Two Type of Test Treatment Months Treatment SVC
(slow vital capacity) 63 83 IC
(inspiratory capacity) 64 69 ERV
(expiratory reserve volume) 62 110 MVV
(maximum ventilatory volume) 19 25 DCO
(diffusion of carbon monoxide MI/min/mm Hg) 27 39 DSB
(diffusion single breath) 42 52 O SAT
(oxygen saturation) 91 95 Observation: Twenty to thirty minutes after initial treatment, tidal volume increases, wheezing stops and an increase in exercise tolerance is observed. Reliance on "Proventil*" (Albuterol made by Schering) is reduced from 1600 mg per day to mg per day within the first two (2) weeks of treatment. Use of oxygen was eliminated immediately when treatment started.
Conclusion: Treatment did the following:
(1) Improved lung function by 20%.
(2) Decreased some medication levels and ceased use of oxygen.
(3) Reactive airway disease is reduced to the point that routine use of inhalers is not needed.
(4) Increased exercise tolerance has been tested and certified as being close to that of a person without emphysema and restrictive airway disease.
Subject has been able to return to full work schedule at previous job.
*Trade-mark (5) No recurrence of decreased pulmonary functions.
(6) Mental attitude has greatly improved.
While the method for treating the disease state in mammalian cells involved in the inflammatory response herein described constitute preferred embodiments of this invention, it is to be understood that the invention is not limited to this precise form of method and that changes may be made therein without departing from the scope of the invention which is defined in the appended claims.
The patient is treated with this inhalation therapy periodically.
Initially, treatments are about four (4) times a day at about six (6) hour intervals.
Treatments were reduced to three (3) times a day at about eight (8) hour intervals after 30 days of therapy. Treatments were further reduced to once a day 60 DAYS
AFTER ONSET OF TREATMENT. After ninety (90) days treatments are three to five times a week.
The following data shows results of various lung capacity and lung *Trade-mark function tests administered before treatment and two (2) months after treatment was commenced.
Before After Two Type of Test Treatment Months Treatment SVC
(slow vital capacity) 63 83 IC
(inspiratory capacity) 64 69 ERV
(expiratory reserve volume) 62 110 MVV
(maximum ventilatory volume) 19 25 DCO
(diffusion of carbon monoxide MI/min/mm Hg) 27 39 DSB
(diffusion single breath) 42 52 O SAT
(oxygen saturation) 91 95 Observation: Twenty to thirty minutes after initial treatment, tidal volume increases, wheezing stops and an increase in exercise tolerance is observed. Reliance on "Proventil*" (Albuterol made by Schering) is reduced from 1600 mg per day to mg per day within the first two (2) weeks of treatment. Use of oxygen was eliminated immediately when treatment started.
Conclusion: Treatment did the following:
(1) Improved lung function by 20%.
(2) Decreased some medication levels and ceased use of oxygen.
(3) Reactive airway disease is reduced to the point that routine use of inhalers is not needed.
(4) Increased exercise tolerance has been tested and certified as being close to that of a person without emphysema and restrictive airway disease.
Subject has been able to return to full work schedule at previous job.
*Trade-mark (5) No recurrence of decreased pulmonary functions.
(6) Mental attitude has greatly improved.
While the method for treating the disease state in mammalian cells involved in the inflammatory response herein described constitute preferred embodiments of this invention, it is to be understood that the invention is not limited to this precise form of method and that changes may be made therein without departing from the scope of the invention which is defined in the appended claims.
Claims (51)
1. Use of an inflammatory mediator selected from pyruvic acid, a salt of pyruvate, and a pyruvate precursor, in the preparation of a medicament for the treatment of inflammation associated with a respiratory disease in a mammal.
2. Use for treating inflammation associated with a respiratory disease in a mammal of an inflammatory mediator selected from pyruvic acid, a salt of pyruvate, and a pyruvate precursor.
3. The use of claim 1 or 2, wherein the respiratory disease is asthma.
4. The use of claim 3, wherein said inflammatory mediator is admixed with at least one additional therapeutic agent, other than albuterol, in a form adapted for administration in a mammal.
5. The use of claim 1 or 2, wherein the respiratory disease is emphysema.
6. The use of claim 1 or 2, wherein the respiratory disease is acute bronchitis.
7. The use of claim 5, wherein the respiratory disease is chronic obstructive emphysema.
8. The use of claim 5, wherein the respiratory disease is centrilobular emphysema.
9. The use of claim 5, wherein the respiratory disease is panacinar emphysema.
10. The use of claim 1 or 2, wherein the respiratory disease is chronic obstructive bronchitis.
11. The use of claim 1 or 2, wherein the respiratory disease is reactive airway disease.
12. The use of claim 1 or 2, wherein the respiratory disease is cystic fibrosis.
13. The use of claim 1 or 2, wherein the respiratory disease is bronchiectasis.
14. The use of claim 13, wherein the respiratory disease is acquired bronchiectasis.
15. The use of claim 1 or 2, wherein the respiratory disease is kartaagener's syndrome.
16. The use of claim 1 or 2, wherein the respiratory disease is atelectasis.
17. The use of claim 16, wherein the respiratory disease is acute atelectasis.
18. The use of claim 16, wherein the respiratory disease is chronic atelectasis.
19. The use of claim 1 or 2, wherein the respiratory disease is pneumonia.
20. The use of claim 1 or 2, wherein the respiratory disease is legionnaires disease.
21. The use of claim 1 or 2, wherein the respiratory disease is psittacosis.
22. The use of claim 1 or 2, wherein the respiratory disease is fibrogenic dust disease.
23. The use of claim 1 or 2, wherein the respiratory disease is a disease due to organic dust.
24. The use of claim 1 or 2, wherein the respiratory disease is a disease due to irritant gases and chemicals.
25. The use of claim 1 or 2, wherein the respiratory disease is a hypersensitivity disease of the lungs.
26. The use of claim 1 or 2, wherein the respiratory disease is an idiopathic infiltrative disease of the lungs.
27. The use of any one of claims 1 to 26, wherein the inflammatory mediator used is pyruvic acid.
28. The use of any one of claims 1 to 26, wherein the salt of pyruvate is selected from the group consisting of:
lithium pyruvate, sodium pyruvate, potassium pyruvate, magnesium pyruvate, calcium pyruvate, zinc pyruvate, manganese pyruvate, and mixtures thereof.
lithium pyruvate, sodium pyruvate, potassium pyruvate, magnesium pyruvate, calcium pyruvate, zinc pyruvate, manganese pyruvate, and mixtures thereof.
29. The use of any one of claims 1 to 26, wherein the inflammatory mediator is selected from the group consisting of pyruvyl-glycine, pyruvyl-alanine, pyruvyl-leucine, pyruvyl-valine, pyruvyl-isoleucine, pyruvyl-phenylalanine, and pyruvamide.
30. The use of any one of claims 1 to 29, wherein the inflammatory mediator is formulated for administration to said mammal by inhalation.
31. The use of any one of claims 1 to 30, wherein at least one additional therapeutic agent selected from the group consisting of antibacterials, antivirals, antifungals, antihistamines, proteins, enzymes, hormones, nonsteroidal anti-inflammatories, cytokines, and steroids, is used.
32. The use of claim 31, wherein the additional therapeutic agent is for administration prior to the inflammatory mediator.
33. The use of claim 31, wherein the additional therapeutic agent for concomitant administration with the inflammatory mediator.
34. The use of claim 31, wherein the additional therapeutic agent is for administration after the inflammatory mediator.
35. The use of any one of claims 1 to 34, wherein the inflammation is caused by white blood cells.
36. The use of any one of claims 1 to 35, wherein the inflammation is treated by achieving a reduction in at least one of the following: oxygen radical production, hydrogen peroxide production, cytokine production, protease production, prostaglandin production, erythema, histamine production or interleukin production.
37. A pharmaceutical composition for treating inflammation associated with a respiratory disease in a mammal, comprising a therapeutically effective amount of an inflammatory mediator selected from pyruvic acid, a salt of pyruvate, and a pyruvate precursor, together with a pharmaceutically acceptable carrier.
38. The pharmaceutical composition of claim 37, wherein the inflammatory mediator is pyruvic acid.
39. The pharmaceutical composition of claim 37, wherein the inflammatory mediator is a salt of pyruvate.
40. The pharmaceutical composition of claim 37, wherein the inflammatory mediator is a pyruvate precursor.
41. The pharmaceutical composition of claim 37, wherein the pyruvate salt is selected from lithium pyruvate, sodium pyruvate, potassium pyruvate, magnesium pyruvate, calcium pyruvate, zinc pyruvate, manganese pyruvate, and mixtures thereof.
42. The pharmaceutical composition of claim 37, wherein the pyruvate salt is sodium pyruvate.
43. The pharmaceutical composition of claim 37, wherein the pyruvate precursor is selected from pyruvyl-glycine, pyruvyl-alanine, pyruvyl-leucine, pyruvyl-valine, pyruvyl-isoleucine, pyruvyl-phenylalanine, pyruvamide, and mixtures thereof.
44. The pharmaceutical composition of any one of claims 37 to 43, wherein the therapeutically effective amount of the inflammatory mediator is from about 0.001 to about 10 grams per dose.
45. The pharmaceutical composition of claim 44, wherein the therapeutically effective amount of the inflammatory mediator is from about 0.001 to about 1 gram per dose.
46. The pharmaceutical composition of claim 45, wherein the therapeutically effective amount of the inflammatory mediator is from about 0.001 to 2.8 mg per dose.
47. The pharmaceutical composition of any one of claims 37 to 46 in a form adapted for inhalation.
48. The pharmaceutical composition of claim 47 adapted for a single inhalation or for repeated inhalations.
49. The pharmaceutical composition of any one of claims 37 to 48, wherein the inflammatory mediator is nebulized.
50. The pharmaceutical composition of any one of claims 37 to 49, wherein the inflammatory mediator is in liquid or solid form with liquid droplets or particle for accessing lung tissue by inhalation.
51. A commercial package comprising the pharmaceutical composition of any one of claims 37 to 50, together with instructions for treatment of inflammation associated with a respiratory disease in a mammal.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US396295P | 1995-09-19 | 1995-09-19 | |
| US60/003,962 | 1995-09-19 | ||
| PCT/US1996/014304 WO1997010818A1 (en) | 1995-09-19 | 1996-09-06 | Method and composition for treating mammalian diseases caused by inflammatory response |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2205112A1 CA2205112A1 (en) | 1997-03-27 |
| CA2205112C true CA2205112C (en) | 2008-11-18 |
Family
ID=21708422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002205112A Expired - Lifetime CA2205112C (en) | 1995-09-19 | 1996-09-06 | Method and composition for treating mammalian diseases caused by inflammatory response |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0804181A4 (en) |
| JP (1) | JP4459303B2 (en) |
| AU (1) | AU719332B2 (en) |
| CA (1) | CA2205112C (en) |
| IL (1) | IL119225A (en) |
| MX (1) | MX9703653A (en) |
| NZ (1) | NZ306832A (en) |
| TW (1) | TW434012B (en) |
| WO (1) | WO1997010818A1 (en) |
| ZA (1) | ZA967833B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4885362B2 (en) * | 1999-05-14 | 2012-02-29 | セルラー サイエンセズ インコーポレイテッド | Methods and compositions for treating nasal and sinus diseases of mammals caused by an inflammatory response |
| JP2004528307A (en) * | 2001-03-15 | 2004-09-16 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | Use of pyruvate and / or derivatives thereof for the treatment of inflammatory conditions mediated by cytokines |
| US6689810B2 (en) * | 2001-08-21 | 2004-02-10 | Cellular Sciences, Inc. | Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
| US6623723B2 (en) * | 2001-08-21 | 2003-09-23 | Cellular Sciences Inc. | Method for treating bronchial constriction and bronchospasm |
| US20030105162A1 (en) * | 2001-08-21 | 2003-06-05 | Celluar Sciences, Inc. | Method for treating bronchial constriction and bronchospasm |
| US8076373B2 (en) * | 2001-09-11 | 2011-12-13 | North Cell Pharmacetical | Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite |
| JP5630750B2 (en) * | 2008-03-18 | 2014-11-26 | 国立大学法人 岡山大学 | Excitatory chemical transmission regulator and screening method thereof |
| WO2018232383A1 (en) * | 2017-06-16 | 2018-12-20 | Vanderbilt University | Methods and compositions for treating microbial inflammation |
| US11571455B2 (en) | 2013-04-11 | 2023-02-07 | Vanderbilt University | Methods and compositions for treating alcoholic liver disease |
| EP3797766A1 (en) * | 2019-09-24 | 2021-03-31 | Evonik Operations GmbH | Compositions for use in reducing inflammation |
| EP4058556A1 (en) * | 2019-11-14 | 2022-09-21 | Merck Patent GmbH | Cell culture media |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1857M (en) * | 1962-03-08 | 1963-06-10 | Roussel Uclaf | New drug in particular for the treatment of diseases of viral origin. |
| US3279997A (en) * | 1963-10-22 | 1966-10-18 | Herbert D Schneyer | Enteric coated calcium lactate tablets containing an antihistamine and thiamine chloride |
| US3879537A (en) * | 1973-09-04 | 1975-04-22 | Scott Eugene J Van | Treatment of ichthyosiform dermatoses |
| US3988470A (en) * | 1974-02-25 | 1976-10-26 | Scott Eugene J Van | Treatment of palmar and plant disturbed keratosis |
| US4158057A (en) * | 1975-03-28 | 1979-06-12 | Stanko Ronald T | Prevention of the accumulation of fatty deposits in the liver |
| US4021572A (en) * | 1975-07-23 | 1977-05-03 | Scott Eugene J Van | Prophylactic and therapeutic treatment of acne vulgaris utilizing lactamides and quaternary ammonium lactates |
| US4197316A (en) * | 1975-07-23 | 1980-04-08 | Scott Eugene J Van | Treatment of dry skin |
| US4234599A (en) * | 1978-10-04 | 1980-11-18 | Scott Eugene J Van | Treatment of skin keratoses with α-hydroxy acids and related compounds |
| US4351835A (en) * | 1981-04-01 | 1982-09-28 | Montefiore Hospital | Method for preventing body fat deposition in mammals |
| US4415576A (en) * | 1981-04-01 | 1983-11-15 | Montefiore Hospital | Method for preventing body fat deposition in mammals |
| US4521375A (en) * | 1982-11-23 | 1985-06-04 | Coopervision, Inc. | Sterilizing treatment with hydrogen peroxide and neutralization of residual amounts thereof |
| DE3302694A1 (en) * | 1983-01-27 | 1984-08-02 | Retheto Filmtechnik Theilemann & Co, 8000 München | ORAL CARE PRODUCTS |
| AU4634685A (en) * | 1984-06-22 | 1986-01-24 | R.L. Veech | Electrolyte solutions and in vivo use thereof |
| US4696917A (en) * | 1985-08-01 | 1987-09-29 | Lindstrom Richard L | Irrigation solution |
| JPS63135370A (en) * | 1986-11-26 | 1988-06-07 | Grelan Pharmaceut Co Ltd | Antiallergic agent |
| IN168530B (en) * | 1987-11-06 | 1991-04-20 | Lyphomed Inc | |
| AU4056089A (en) * | 1988-07-20 | 1990-02-19 | Amgen, Inc. | Method of treating inflammatory disorders by reducing phagocyte activation |
| JP2794021B2 (en) * | 1988-11-02 | 1998-09-03 | エーザイ株式会社 | Transdermal preparation containing azelastine or its salts |
| AU7699191A (en) * | 1990-03-30 | 1991-10-30 | Amgen, Inc. | Respiratory burst suppression factor |
| US5210098A (en) * | 1990-09-21 | 1993-05-11 | Regents Of The University Of Minnesota | Use of pyruvate to treat acute renal failure |
| US5296370A (en) * | 1990-10-04 | 1994-03-22 | Rutgers, The State University | Repair medium for the resuscitation of injured cells |
| US5648380A (en) * | 1991-03-01 | 1997-07-15 | Warner-Lambert Company | Anti-inflammatory wound healing compositions and methods for preparing and using same |
| WO1993016690A1 (en) * | 1992-02-25 | 1993-09-02 | Warner-Lambert Company | Cytoprotective compositions containing pyruvate and antioxidants |
| US5256697A (en) * | 1992-04-16 | 1993-10-26 | Abbott Laboratories | Method of administering pyruvate and methods of synthesizing pyruvate precursors |
| JP3236658B2 (en) * | 1992-04-27 | 2001-12-10 | 花王株式会社 | Bronchodilator |
| US5536751A (en) * | 1994-05-09 | 1996-07-16 | The United States Of America As Represented By The Secretary Of The Army | Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof |
-
1996
- 1996-09-06 NZ NZ306832A patent/NZ306832A/en not_active IP Right Cessation
- 1996-09-06 EP EP96929932A patent/EP0804181A4/en not_active Withdrawn
- 1996-09-06 WO PCT/US1996/014304 patent/WO1997010818A1/en active Application Filing
- 1996-09-06 AU AU69159/96A patent/AU719332B2/en not_active Ceased
- 1996-09-06 MX MX9703653A patent/MX9703653A/en unknown
- 1996-09-06 CA CA002205112A patent/CA2205112C/en not_active Expired - Lifetime
- 1996-09-06 JP JP51274197A patent/JP4459303B2/en not_active Expired - Lifetime
- 1996-09-09 IL IL11922596A patent/IL119225A/en not_active IP Right Cessation
- 1996-09-17 ZA ZA967833A patent/ZA967833B/en unknown
- 1996-09-18 TW TW085111379A patent/TW434012B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2205112A1 (en) | 1997-03-27 |
| EP0804181A1 (en) | 1997-11-05 |
| TW434012B (en) | 2001-05-16 |
| EP0804181A4 (en) | 2005-02-02 |
| JP4459303B2 (en) | 2010-04-28 |
| MX9703653A (en) | 1998-07-31 |
| IL119225A0 (en) | 1996-12-05 |
| WO1997010818A1 (en) | 1997-03-27 |
| AU6915996A (en) | 1997-04-09 |
| NZ306832A (en) | 2001-04-27 |
| IL119225A (en) | 2000-09-28 |
| ZA967833B (en) | 1997-06-02 |
| JPH10509463A (en) | 1998-09-14 |
| AU719332B2 (en) | 2000-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5798388A (en) | Method and composition for treating mammalian diseases caused by inflammatory response | |
| AU2006213755B2 (en) | Method and composition for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite | |
| EP0792163B1 (en) | Acne treating-wound healing compositions containing a pyruvate, an antioxidant and a mixture of fatty acids | |
| CA2457983C (en) | Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide | |
| JP3506701B2 (en) | Wound healing composition, its preparation and use | |
| AU2002329762A1 (en) | Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide | |
| CA2205112C (en) | Method and composition for treating mammalian diseases caused by inflammatory response | |
| AU1328501A (en) | Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase | |
| US7122578B2 (en) | Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration | |
| AU4275793A (en) | Cytoprotective compositions containing pyruvate and antioxidants | |
| JP2011190274A (en) | Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response | |
| CZ20021559A3 (en) | Use of dinitrogen dioxide for producing a medicament intended for treating airways constriction | |
| AU674131C (en) | Wound healing compositions containing a pyruvate, an antioxidant and a mixture of fatty acids | |
| EP0753309A2 (en) | Preparation of lactoferrin (or analogous proteins) and desferrioxamine methanesulfonate (or other metal ion chelators) for the therapy of viral infectious diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20160906 |